It is estimated that a third of Americans have a fatty liver. Nonalcoholic fatty liver disease is a very common liver condition. Nonalcoholic steatohepatitis, or NASH, the more aggressive form of nonalcoholic fatty liver disease, is associated with increased cardiac risk and liver-related mortality.
The VCU findings may provide researchers with potential new targets for treatment and also allow clinicians to further refine how they assess cardiovascular risk and develop ways to reduce it in individuals with a more aggressive form of nonalcoholic fatty liver disease called nonalcoholic steatohepatitis, or NASH.
In the study, published in the May issue of Cell Metabolism, the team has shown that there is not only increased production of cholesterol but a decreased expression of the receptor that takes up cholesterol from the blood. This would be expected to both enhance cholesterol output from the liver and reduce its removal, thereby making it more available to enter blood vessels and contribute to cardiovascular disease. The liver not only makes cholesterol, but also takes up cholesterol from the blood.
"This indicates that there is excessive cholesterol production in the liver when one develops fatty liver disease," said lead investigator Arun Sanyal, M.D., professor and chair in the Division of Gastroenterology, Hepatology and Nutrition in the VCU School of Medicine.
"This may be important both to drive the disease towards cirrhosis and to increase the risks of heart disease in those with fatty liver disease," said Sanyal.
Sanyal collaborated with VCU colleagues in the VCU Division of Gastroenterology, Hepatology and Nutrition, the Department of Surgery and the Department of Pathology.
The work was supported in part by grants from the National Institutes of Health, grant numbers: 5R01DK081410-03, K24 DK 02755 and T32 DK-007150-33.
EDITOR'S NOTE: A copy of the study is available for reporters by contacting the journal at email@example.com.
About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
Sathya Achia Abraham | EurekAlert!
Further reports about: > Commonwealth > Division > Gastroenterology > Hepatology > Medical Wellness > Medicine > NASH > Nonalcoholic > Nonalcoholic fatty liver > Nonalcoholic steatohepatitis > VCU > blood vessel > cardiovascular disease > fatty liver > liver disease > nonalcoholic fatty liver disease
Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München
Second research flight into zero gravity
21.10.2016 | Universität Zürich
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences